Cusmai A - Search Results

1

Ladiratuzumab vedotin for metastatic triple negative cancer: preliminary results, key challenges, and clinical potential.

Rizzo A, Cusmai A, Acquafredda S, Rinaldi L, Palmiotti G. Rizzo A, et al. Among authors: cusmai a. Expert Opin Investig Drugs. 2022 Jun;31(6):495-498. doi: 10.1080/13543784.2022.2042252. Epub 2022 Feb 17. Expert Opin Investig Drugs. 2022. PMID: 35171746 No abstract available.

2

Dose intensity and efficacy of the combination of everolimus and exemestane (EVE/EXE) in a real-world population of hormone receptor-positive (ER+/PgR+), HER2-negative advanced breast cancer (ABC) patients: a multicenter Italian experience.

Ciccarese M, Fabi A, Moscetti L, Cazzaniga ME, Petrucelli L, Forcignanò R, Lupo LI, De Matteis E, Chiuri VE, Cairo G, Febbraro A, Giordano G, Giampaglia M, Bilancia D, La Verde N, Maiello E, Morritti M, Giotta F, Lorusso V, Latorre A, Scavelli C, Romito S, Cusmai A, Palmiotti G, Surico G. Ciccarese M, et al. Among authors: cusmai a. Breast Cancer Res Treat. 2017 Jun;163(3):587-594. doi: 10.1007/s10549-017-4213-9. Epub 2017 Mar 28. Breast Cancer Res Treat. 2017. PMID: 28353061

3

Systemic Treatment for Metastatic Biliary Tract Cancer: State of the Art and a Glimpse to the Future.

Rizzo A, Ricci AD, Cusmai A, Acquafredda S, De Palma G, Brandi G, Palmiotti G. Rizzo A, et al. Among authors: cusmai a. Curr Oncol. 2022 Jan 27;29(2):551-564. doi: 10.3390/curroncol29020050. Curr Oncol. 2022. PMID: 35200550 Free PMC article. Review.

4

Second-line fluoropyrimidine-based doublet chemotherapy for advanced biliary tract cancer: a new standard of care?

Rizzo A, Cusmai A, Palmiotti G. Rizzo A, et al. Among authors: cusmai a. Expert Rev Gastroenterol Hepatol. 2022 Mar;16(3):201-203. doi: 10.1080/17474124.2022.2047652. Epub 2022 Mar 2. Expert Rev Gastroenterol Hepatol. 2022. PMID: 35220859 No abstract available.

5

Fluoropyrimidine-based doublet chemotherapy as second-line treatment for advanced biliary tract cancer: a meta-analysis of ABC-06 and NIFTY.

Rizzo A, Cusmai A, Giovannelli F, Acquafredda S, Rinaldi L, Misino A, Palmiotti G. Rizzo A, et al. Among authors: cusmai a. Expert Rev Gastroenterol Hepatol. 2022 Mar;16(3):273-278. doi: 10.1080/17474124.2022.2047651. Epub 2022 Mar 2. Expert Rev Gastroenterol Hepatol. 2022. PMID: 35220866

6

Combination systemic therapies with immune checkpoint inhibitors in biliary tract cancer: effective but not enough?

Rizzo A, Cusmai A, Ricci AD, Brandi G, Palmiotti G. Rizzo A, et al. Among authors: cusmai a. Expert Rev Gastroenterol Hepatol. 2022 Apr;16(4):307-310. doi: 10.1080/17474124.2022.2055548. Epub 2022 Mar 22. Expert Rev Gastroenterol Hepatol. 2022. PMID: 35302426 No abstract available.

7

Impact of Proton Pump Inhibitors and Histamine-2-Receptor Antagonists on Non-Small Cell Lung Cancer Immunotherapy: A Systematic Review and Meta-Analysis.

Rizzo A, Cusmai A, Giovannelli F, Acquafredda S, Rinaldi L, Misino A, Montagna ES, Ungaro V, Lorusso M, Palmiotti G. Rizzo A, et al. Among authors: cusmai a. Cancers (Basel). 2022 Mar 9;14(6):1404. doi: 10.3390/cancers14061404. Cancers (Basel). 2022. PMID: 35326555 Free PMC article. Review.

8

KEYNOTE-522, IMpassion031 and GeparNUEVO: changing the paradigm of neoadjuvant immune checkpoint inhibitors in early triple-negative breast cancer.

Rizzo A, Cusmai A, Acquafredda S, Giovannelli F, Rinaldi L, Misino A, Palmiotti G. Rizzo A, et al. Among authors: cusmai a. Future Oncol. 2022 Jun;18(18):2301-2309. doi: 10.2217/fon-2021-1647. Epub 2022 Apr 5. Future Oncol. 2022. PMID: 35378995 Review.

9

Which role for predictors of response to immune checkpoint inhibitors in hepatocellular carcinoma?

Rizzo A, Cusmai A, Gadaleta-Caldarola G, Palmiotti G. Rizzo A, et al. Among authors: cusmai a. Expert Rev Gastroenterol Hepatol. 2022 Apr;16(4):333-339. doi: 10.1080/17474124.2022.2064273. Epub 2022 Apr 10. Expert Rev Gastroenterol Hepatol. 2022. PMID: 35403533

10

Adenosine pathway inhibitors: novel investigational agents for the treatment of metastatic breast cancer.

Rizzo A, Massafra R, Fanizzi A, Rinaldi L, Cusmai A, Latorre A, Zaccaria GM, Ronchi M, Telegrafo M, Gadaleta-Caldarola G, Giotta F, Lorusso V, Palmiotti G. Rizzo A, et al. Among authors: cusmai a. Expert Opin Investig Drugs. 2022 Jul;31(7):707-713. doi: 10.1080/13543784.2022.2078191. Epub 2022 May 18. Expert Opin Investig Drugs. 2022. PMID: 35575038

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

33 results

Search Page

Filters